It belongs to the same broad family as the GLP-1 medicines already in use, but it adds a third mechanism
In the definitive SURMOUNT-5 head-to-head trial (NEJM 2025), tirzepatide produced ~20% weight loss vs
This bioactive compound has been studied for its potential to support scalp health and encourage a healthy hair growth environment
Starting at 5 mg instead of 2.5 mg Some providers start patients at 5 mg when: The patient was on maximum-dose semaglutide (2.0 to 2.4 mg) for 6 or more months with good tolerance The patient experienced no significant GI side effects on semaglutide Weight loss has been stalled for 8 or more weeks despite medication compliance The patient has a BMI above 40 and more aggressive weight loss is clinically appropriate A study examining GLP-1 to tirzepatide transitions found that patients who started at 5 mg had manageable side effects and comparable outcomes to those who started at 2.5 mg, provided they had prior GLP-1 experience
(ii) Pathway-Aligned Endpoints
2019;8doi:10.12688/f1000research.17076.1 Dutta S, Sengupta P, Roychoudhury S, Chakravarthi S, Wang CW, Slama P
